Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

NDA submitted for empagliflozin in type 2 diabetes

March 26, 2013

Intrathecal idursulfase proves effective in children with Hunter's syndrome

March 26, 2013

Metabolex patents new GPBA receptor agonists

March 25, 2013

Teriparatide as the first anabolic therapy for osteogenesis imperfecta

March 25, 2013

Enrollment begins in FREEDOM phase III program for once- or twice-yearly diabetes therapy

March 22, 2013

BioMarin reports phase I/II data for BMN-701 in Pompe's disease

March 21, 2013

Acasti Pharma reports preliminary data from CaPre trial

March 21, 2013

Novo Nordisk completes phase I study of new oral insulin

March 21, 2013

Alda-1 exerts protective effect against neuronal death in HE

March 21, 2013

Pharmacokinetic evaluation of a novel intrathecal-lumbar formulation of idursulfase

March 20, 2013

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...